Mode
Text Size
Log in / Sign up
N/A Completed N=207 Randomized Single-blind Prevention

A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians

Source: ClinicalTrials.gov NCT02266576 ↗
Enrolled (actual)
207
Serious AEs
0.0%
Results posted
Jan 2020
Primary outcomePrimary: Change From Baseline in Body Mass Index (BMI) Through Month 12 — 37.0; 37.8; -.7; -.3 kg/m^2 — p=0.04

Summary

The goal of the proposed research is to identify effective patient-centered strategies to prevent diabetes in high-risk populations in real world settings. The investigators will accomplish this by conducting a randomized controlled trial comparing an enhanced Diabetes Prevention Program addressing psychosocial stressors to a standard version in a high-risk population of urban American Indian and Alaska Native people within a primary care setting.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Body Mass Index (BMI) Through Month 12
37.0; 37.8; -.7; -.3; -.5; -.3 0.04 sig
PRIMARY
Change From Baseline in the Quality of Life Short Form Survey (SF-12)
41.5; 40.2; 3.0; 3.1; 2.2; 2.9 0.004 sig
SECONDARY
Change From Baseline in Food Frequency Questionnaire (FFQ) Score as a Measure of Healthy and Unhealthy Diet Choices
22.6; 22.8; -.6; .4; 0.4; -0.4
SECONDARY
Change From Baseline in Physical Activity Measured in Metabolic Equivalents (MET) Per Week
1389.1; 1541; -94.3; -23.5; 144.6; -241.6
SECONDARY
Change From Baseline in the Center for Epidemiologic Studies - Depression Scale (CES-D) as a Measure of Mental Health Symptoms
13.9; 12.2; -2.3; 0.04; -1.2; -0.1
SECONDARY
Change From Baseline in Empowerment
46.2; 47.1; 0.2; -0.4; -0.3; 0.9

Eligibility Criteria

Inclusion Criteria

  • Urban of Indigenous Ancestry from the Americas (North, Central and South America)
  • Men and women
  • BMI Between 30-55
  • Not diagnosed with Type II Diabetes
  • At least one of the following criterion
  • Triglycerides: 150mg/dL or higher
  • Reduced HDL: 130/80 or current treatment with antihypertensives
  • Fasting glucose: >100mg/dL

Exclusion Criteria

  • Significant medical comorbidities, including uncontrolled metabolic disorders (e.g., thyroid, diabetes, renal, liver), unstable heart disease, heart failure, and ongoing substance abuse;
  • On greater than 10 prescription medications.
  • Psychiatric disorders requiring atypical antipsychotics or multiple medications;
  • Inappropriate for moderate exercise according to the Revised Physical Activity Readiness Questionnaire;
  • Pregnant, planning to become pregnant, or lactating;
  • Family household member already enrolled in the study;
  • Already enrolled or planning to enroll in a clinical trial that would limit full participation in the study;
  • Resident of a long term care facility;
  • Lack of spoken English by patient or a household member > 18 y who can serve as interpreter;
  • Plans to move during the study period (9 months post-randomization);
  • Investigator discretion for clinical safety or adherence reasons (e.g., unstable housing, chronic pain).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02266576). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search